menu
    • menu

    Company profile for Veranova

    Veranova-PSE
    News
    HPAPI for Drug Development and Delivery

    09 Dec 2024

    // PRESS RELEASE

    Veranova Recognized As One Of SOCMA’s 25 Companies With Programs

    08 Nov 2024

    // PRESS RELEASE

    Cécile Maupas Directly Responsible For Bitrex Commercial Operations

    01 Nov 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Veranova

    Contact Supplier

    Website

    Antibody Engineering

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/3R1DIhV4gtk

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Veranova: A CDMO that manages complexity with confidence.

    Related CompaniesRelated Companies

    About

    Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the challenges of the global healthcare industry, and nurturing long-standing, trusted customer relationships. Operating within two divisions, Generics and Originators, we deliver a differentiated service offering to pharma and biotech customers for every stage in the drug development lifecycle.
    Macfarlan Smith Limited is trading as Veranova in the United Kingdom.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VeranovaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    435 Devon Park Drive, Suite 400, Wayne, PA. 19807
    Telephone
    Telephone
    +1 4845810160
    Client Email
    Email
    info@veranova.com
    Client Website
    Website
    https://veranova.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/veranovalife/
    youtube
    YouTube
    https://www.youtube.com/@veranova1745/videos
    Twitter
    Twitter
    https://x.com/veranova_life/
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    A PHP Error was encountered

    Severity: Warning

    Message: Undefined variable $tile1

    Filename: tabs/exhibitions.php

    Line Number: 43

    Backtrace:

    File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
    Line: 43
    Function: _error_handler

    File: /var/www/html/application/models/CmnPec.php
    Line: 1625
    Function: view

    File: /var/www/html/application/views/include/party/query.php
    Line: 575
    Function: create

    File: /var/www/html/application/views/include/party/indexNew.php
    Line: 70
    Function: include

    File: /var/www/html/application/views/commonNew.php
    Line: 445
    Function: include

    File: /var/www/html/application/controllers/PharmaServices.php
    Line: 4651
    Function: view

    File: /var/www/html/index.php
    Line: 224
    Function: require_once

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    This week, SpeakPharma interviews Mike Riley, CEO of Veranova, a leading contract development and manufacturing organization (CDMO) confidently mastering complex APIs as it marks its second year as an independent company. Riley discusses Veranova’s key achievements, including a US$ 30 million investment in their Devens, Massachusetts (US) site to expand capabilities in antibody-drug conjugates (ADCs) and highly potent APIs (HPAPIs), and how it is navigating the increasing complexity of molecules. 🔑 HIGHLIGHTS// Veranova’s key achievements / navigating the increasing complexity of molecules Veranova is celebrating its second year as a stand-alone company. Can you share Veranova’s key milestones and achievements in its first two years? We have achieved incredible milestones over the last two years, thanks to the dedication and hard work of our team. Our first 12 months focused on establishing ourselves as an independent CDMO by building on the 50 years of expertise that we brought with us. In addition, we expanded our capabilities and applied a more agile approach available to us as a company singularly focused on life sciences. This has allowed us to move into our second year with clear and strategic goals for generating growth in our sites, people, capabilities, and offerings. Since being appointed as CEO in May 2023, I’ve had the pleasure of witnessing some exciting growth milestones of my own. Most recently, we announced an estimated US$ 30 million investment in our Devens, Massachusetts, site. This expansion will allow us to build upon existing development and manufacturing capabilities in ADCs and HPAPIs that will address the growing demand for strong US-based capacity in these key drug modalities. We also appointed our Advisory Board, thereby bolstering Veranova’s in-house expertise. Made up of four distinguished leaders in pharma and biopharma – including Dr. Carolyn Bertozzi, the 2022 Nobel Laureate in Chemistry – the Board has provided thought-leadership, guidance and expertise as we develop and execute our strategic growth and ideas. We were also proud to be recognized as one of the Society of Chemical Manufacturers and Affiliates’ 12 companies for industry-leading safety programs in 2023 and as a part of the Medicine Maker’s Power List in 2024. 🔑 HIGHLIGHTS// US$ 30 million investment in our Devens, Massachusetts, site / appointed our Advisory Board Molecules are becoming increasingly complex. Can you elaborate on how Veranova’s current capabilities are strategically designed to address this trend in the coming years? The pharmaceutical pipeline is witnessing an increasing number of complex and highly potent molecules. This trend is driven by the demand for more targeted, patient-centric therapeutics and the focus on innovative modalities such as ADCs and other bioconjugates. At Veranova, our expertise, world-class facilities, and scientific excellence enable us to provide our customers with the clarity and solutions needed to manage this development and manufacturing complexity and ultimately deliver the required treatments to customers and patients. Our people are key to this approach. We have an expert team ready to collaborate with customers at any point, from early development through large-scale commercial production. Our services include world-leading crystallization development, process development, and specialized manufacturing expertise for complex synthetic molecules, including those requiring chromatography capabilities. In many cases, we can provide all these under one roof. Our service offering to our customers is also based on the foundational element of strong quality and compliance systems. We operate multiple facilities approved by the US FDA, UK’s MHRA and other regulatory authorities and are continually focused on ways to strengthen our global quality management system. Looking ahead, we are focused on continually investing in our facilities and team to meet growing complexity, as evidenced by our recent announcement of new investment in our Devens site. This investment signals our commitment to providing state-of-the-art capacity and capabilities to enable these next-generation therapies to reach patients. It is a key milestone as we advance Veranova’s broader growth strategy. 🔑 HIGHLIGHTS// provide our customers with clarity and solutions / world-leading crystallization development / expertise for complex synthetic molecules / strong quality and compliance systems How is Veranova approaching the challenge of designing and manufacturing effective linker molecules for ADCs? As a leader in complex linker-payload synthesis, Veranova is committed to unlocking the life-changing potential of ADCs without letting their complexities slow down the development of much-needed cancer therapies. ADCs are intricate, multi-component molecules that require extensive expertise and agile collaboration to overcome unique development challenges. With over a decade of experience in ADC linker-payload systems, we have developed the ability to anticipate challenges and avoid common pitfalls. The ADC linker-payload components are complex structures that are difficult to crystallize and require specialized high-potent handling. Veranova’s differentiated combination of world-leading crystallization development capabilities, complex synthesis experience, chromatography expertise and high-potent-handling experience put us in a unique position to solve these challenges for customers and speed their products to the clinic. We prioritize getting it right the first time, minimizing change orders and ensuring high-quality results. We have developed a robust phase-appropriate strategy that is backed by state-of-the-art analytical equipment and regulatory procedures to ensure our partners can rapidly progress their ADC projects from pre-clinical to commercialization. 🔑 HIGHLIGHTS// unlocking the life-changing potential of ADCs / ensuring our partners can rapidly progress their ADC projects Can you specify how Veranova is using artificial intelligence (AI) to optimize manufacturing processes that can reduce costs and environmental footprint as well as speed up development? In May 2024, Veranova announced a partnership with Phorum.AI to leverage AI to optimize pharmaceutical manufacturing processes. This collaboration aims to enable the rapid development of processes that can drive efficiency and reduce costs while maximizing environmental sustainability. Our goal is to combine Veranova’s extensive empirical manufacturing dataset of owned APIs and drug master files with Phorum.AI’s computational chemistry engine in order to create a more powerful process-development tool for the benefit of Veranova’s and Phorum’s customers. At Veranova, we are constantly looking to employ innovative technologies and approaches to improve efficiency, accelerate time to market and reduce environmental footprint. We have the means to work with a variety of partners who have unique project requirements, without sacrificing time to market.  🔑 HIGHLIGHTS// partnership with Phorum.AI / create a more powerful process-development tool / improve efficiency, accelerate time to market and reduce environmental footprint

    Impressions: 2480

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market

    #SpeakPharma With Veranova
    10 Sep 2024
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-26327.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-1658294699.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Veranova & Phorum.AI Partner to Boost Chemistry with AI

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-53011.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Product Under Development 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-16224.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Physchem Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-61276.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Pharmorphix

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-37959.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Crystallization Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-40990.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Analytical Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-58681.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Pharmorphix Solid form and Particle Engineering

    read-more

      https://www.pharmacompass.com/pdf/party/content/veranova-party-content-95098.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    JM Health rebrands as Veranova

    read-more

      https://www.pharmacompass.com/pdf/party/content/johnson-matthey-plc-party-content-1654146392.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2020

    read-more

      https://www.pharmacompass.com/pdf/party/content/johnson-matthey-plc-party-content-1633922688.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3044

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    HPAPI for Drug Development and Delivery
    HPAPI for Drug Development and Delivery

    09 Dec 2024

    // PRESS RELEASE

    https://veranova.com/news/hpapi-for-drug-development-and-delivery/

    PRESS RELEASE
    09 Dec 2024
    Share Share
    Veranova Recognized As One Of SOCMA’s 25 Companies With Programs
    Veranova Recognized As One Of SOCMA’s 25 Companies With Programs

    08 Nov 2024

    // PRESS RELEASE

    https://veranova.com/news/veranova-recognized-as-one-of-socmas-25-companies-with-industry-leading-safety-programs/

    PRESS RELEASE
    08 Nov 2024
    Share Share
    Cécile Maupas Directly Responsible For Bitrex Commercial Operations
    Cécile Maupas Directly Responsible For Bitrex Commercial Operations

    01 Nov 2024

    // PRESS RELEASE

    https://veranova.com/news/veranova-announces-cecile-maupas-now-directly-responsible-for-bitrex-commercial-operations-strengthening-veranovas-commitment-to-safety-and-innovation/

    PRESS RELEASE
    01 Nov 2024
    Share Share
    Veranova Expands Advisory Board With Appointment Of Dr. Rajni
    Veranova Expands Advisory Board With Appointment Of Dr. Rajni

    07 Oct 2024

    // PRESS RELEASE

    https://veranova.com/news/veranova-expands-advisory-board-with-appointment-of-dr-rajni-aneja-and-dr-bradley-l-pentelute/

    PRESS RELEASE
    07 Oct 2024
    Share Share
    Nutriband Licenses Bitrex® Brand Aversive Agent For AVERSA™ Patch
    Nutriband Licenses Bitrex® Brand Aversive Agent For AVERSA™ Patch

    20 Sep 2024

    // PRESS RELEASE

    https://veranova.com/news/nutriband-licenses-bitrex-brand-aversive-agent-for-its-lead-product-aversa-fentanyl-trandsdermal-patch/

    PRESS RELEASE
    20 Sep 2024
    Share Share
    The Evolution of the CDMO Industry
    The Evolution of the CDMO Industry

    25 Aug 2024

    // PRESS RELEASE

    https://veranova.com/news/the-evolution-of-the-cdmo-industry/

    PRESS RELEASE
    25 Aug 2024
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Veranova full-view

    TOP RANKED SUPPLIER FOR:

    Controlled Substance API Development
    full-view
    Solid State Studies
    full-view
    End-to-end CDMO for ADCs
    full-view
    Opiate Based Controlled Substances
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Macfarlan Smith Limited and get a quotation

    Macfarlan Smith Limited is a supplier offers 77 products (APIs, Excipients or Intermediates).

    Find a price of Apomorphine Hydrochloride bulk with DMF, CEP, JDMF offered by Macfarlan Smith Limited

    Find a price of Buprenorphine Hydrochloride bulk with DMF, CEP, JDMF offered by Macfarlan Smith Limited

    Find a price of Carboplatin bulk with DMF, CEP, JDMF offered by Macfarlan Smith Limited

    Find a price of Cisplatin bulk with DMF, CEP, JDMF offered by Macfarlan Smith Limited

    Find a price of Methylphenidate Hydrochloride bulk with DMF, CEP, JDMF offered by Macfarlan Smith Limited

    Find a price of Alfentanil Hydrochloride bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Buprenorphine bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Codeine Phosphate bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Fentanyl bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Fentanyl Citrate bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Hydromorphone Hydrochloride bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Methylphenidate Hydrochloride bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Morphine Sulfate bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Naloxone Hydrochloride bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Naltrexone Hydrochloride bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Oxaliplatin bulk with DMF, JDMF offered by Macfarlan Smith Limited

    Find a price of Oxycodone Hydrochloride bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Remifentanil bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Sufentanil Citrate bulk with DMF, CEP offered by Macfarlan Smith Limited

    Find a price of Alfentanil Hydrochloride bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Amphetamine bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Amphetamine Aspartate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Auranofin bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Benzhydrocodone Hydrochloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Bimatoprost bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Cannabidiol bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Carmustine bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Clevidipine bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Cocaine Hydrochloride bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Codeine Phosphate bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Dantrolene bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Decitabine bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Dexmethylphenidate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Dextroamphetamine Saccharate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Difenoxin Hydrochloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Dihydrocodeine Tartrate bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Diphenoxylate Hydrochloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Dofetilide bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Edrophonium Chloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Epoprostenol Sodium bulk with JDMF offered by Macfarlan Smith Limited

    Find a price of Ethacrynic Acid bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Fentanyl bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Fentanyl Citrate bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Fluvoxamine bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Hydrocodone Bitartrate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Ketoprofen bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Lenalidomide bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Lisdexamfetamine Dimesylate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Lurasidone Hydrochloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Methadone Hydrochloride bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Methamphetamine Hydrochloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Methylphenidate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Morphine Hydrochloride bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Nintedanib Esylate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Oxycodone Hydrochloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Oxymorphone Hydrochloride bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Pirfenidone bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Roflumilast bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Sodium Oxybate bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Sufentanil Citrate bulk with CEP offered by Macfarlan Smith Limited

    Find a price of Tetrahydrocannabinol bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Travoprost bulk with DMF offered by Macfarlan Smith Limited

    Find a price of Atropine Sulfate bulk offered by Macfarlan Smith Limited

    Find a price of Calcium Oxybate bulk offered by Macfarlan Smith Limited

    Find a price of Codeine bulk offered by Macfarlan Smith Limited

    Find a price of Codeine Sulfate bulk offered by Macfarlan Smith Limited

    Find a price of Diamorphine Hydrochloride bulk offered by Macfarlan Smith Limited

    Find a price of Dihydrocodeine Hydrogen Tartrate bulk offered by Macfarlan Smith Limited

    Find a price of Fentanyl Hydrochloride bulk offered by Macfarlan Smith Limited

    Find a price of Isoproterenol Hydrochloride bulk offered by Macfarlan Smith Limited

    Find a price of Magnesium Oxybate bulk offered by Macfarlan Smith Limited

    Find a price of Miglustat bulk offered by Macfarlan Smith Limited

    Find a price of Morphine Tartrate bulk offered by Macfarlan Smith Limited

    Find a price of Nabilone bulk offered by Macfarlan Smith Limited

    Find a price of Opium bulk offered by Macfarlan Smith Limited

    Find a price of Oxycodone Terephthalate bulk offered by Macfarlan Smith Limited

    Find a price of Potassium Oxybate bulk offered by Macfarlan Smith Limited

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search